Insulin-like growth factor 1 (IGF1) was considered a potential candidate for the treatment of
heart failure. However, some animal studies and clinical trials have questioned whether
elevating IGF1 chronically is beneficial. Secondary effects of increased serum IGF1 levels on
other tissues may explain these unfavorable results. The aim of the current study was to
examine the role of IGF1 in cardiac myocytes in the absence of secondary effects, and to
elucidate downstream signaling pathways and transcriptional regulatory effects of the IGF1 …